Healthcare: Should You Stick With Gilead Sciences?
Industry Focus - Podcast tekijän mukaan The Motley Fool
Kategoriat:
Gilead Sciences has been one of biopharma's worst performers, and demand for its hepatitis C drugs has yet to bottom. Can its R&D program jump start investor optimism? Stocks: GILD
